{"prompt": "['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', 'Age at first diagnosis of psoriasis', 'Prior psoriasis therapies', 'Any previous and concomitant topical therapies within the last 3 months before', 'screening will be documented in the CRF. Any systemic psoriasis therapy and', 'phototherapy will be documented in the CRF.', 'Reason(s) for therapy discontinuation or change', 'Psoriasis arthritis (yes / no; verified diagnosis (i.e. diagnosed by a rheumatologist)', 'Involvement of nails (yes / no)', 'Involvement of scalp (yes / no)', '12.3.4 Nicotine Anamnesis', 'Current smoker, past smoker, non-smoker', 'For current and past smoker:', 'Cigarettes per day', 'Years being a smoker (Start date, end date in case of previous smoker)', 'Pack per year (cigarettes per day X years being a smoker / 20)', 'Page 46 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '13', 'Adverse Event Reporting', '13.1', 'Definitions', 'Adverse Event (AE):', 'Any untoward medical occurrence in a patient or clinical investigation patient administered a', 'pharmaceutical product and which does not necessarily have to have a causal relationship', 'with this treatment.', 'An AE can therefore be any unfavorable and unintended sign (including an abnormal', 'laboratory finding, for example), symptom, or disease temporally associated with the use of a', 'medicinal product, whether or not considered related to the medicinal product.', 'Adverse Drug Reaction (ADR):', 'All noxious and unintended responses to a medicinal product related to any dose should be', 'considered adverse drug reactions.', 'Unexpected Adverse Drug Reaction:', 'An adverse reaction, the nature or severity of which is not consistent with the applicable', 'product information (e.g., the IB for Otezla).', 'Serious adverse event (SAE):', 'A SAE is any AE that:', 'results in death', \"is life-threatening (the term life-threatening' refers to an event in which the patient\", 'was at risk of death at the time of the event; it does not refer to an event which', 'hypothetically might have caused death if it was more severe.)', 'requires in-patient hospitalization or prolongation of existing hospitalization,', 'except of:', '-', 'An overnight stay in the hospital that is only due to transportation, organization, or', 'accommodation problems and without medical background does not need to be', 'handled/ documented as a SAE.', '-', 'Hospitalization, that was planned before inclusion of the patient in the study for', 'elective operations or treatments does not need to be handled/ documented as a', 'SAE.', 'results in persistent or significant disability / incapacity (i.e., a substantial', \"disruption in a patient's ability to conduct normal activities of daily living)\", 'is a congenital anomaly / birth defect', 'is an important medical event that, while it may not result in death or be', 'immediately life-threatening or requires / prolongs hospitalization, may jeopardize', 'the patient and / or may require medical or surgical intervention to prevent one of', 'the outcomes listed above. Examples of such events are intensive treatment in', 'an emergency room or at home for allergic bronchospasm; blood dyscrasias or', 'convulsions that do not result in hospitalization; or the development of drug', 'dependency or drug abuse.', 'Page 47 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', 'In-patient hospitalization is considered to have occurred if the patient has had to stay for a', 'night at the hospital. The criterion for prolongation of hospitalization is also defined as an extra', 'night at the hospital. This does not include an emergency room visit or admission to an', 'outpatient facility. Hospitalization for an elective or planned procedure to treat a pre-existing', 'condition is not considered an SAE unless it results in one of the outcomes listed above (but it', 'has to be documented as planned).', '13.2 Record of Adverse Events', \"All AEs from baseline (visit 2, onset of treatment) until the patient's last study visit and all SAEs\", 'upon ICF signature (visit 1) until 30 days after the patient has stopped study participation as', 'well as those SAEs made known to the investigator at any time thereafter that are suspected', 'of being related to the investigational product will be collected.', 'AEs / SAEs will be recorded according to the ICH E6 guidelines on an AE page of the CRF.', 'SAEs will be additionally documented on a SAE report form. Documentation includes the', 'following information: description of AEs in detail including the date of onset, stop date,', 'intensity, relationship of the AE to study drug, action(s) taken, seriousness, time course,', 'duration and outcome. There should be an attempt to report a diagnosis rather than signs,', 'symptoms or abnormal laboratory values.', 'The clinical intensity of an AE is classified as:', 'Mild:', 'Signs and symptoms which could be easily tolerated and are transient.', 'Moderate:', 'Causes discomfort and interferes with normal functioning and interrupts the', \"patient's usual activities but is tolerable.\", 'Severe:', 'Affects considerable usual daily activities, prevents the patient from carrying out', 'his / her daily activities.', 'An AE is considered to be related to the investigational product if a causal relationship between', 'the investigational product and the AE is at least a reasonable possibility (assessed as', '\\'related\\', \"probable\\' or \\'possible\\'), i.e. the relationship cannot be ruled out. If an AE is', 'considered not to be related to the investigational product, the degree of causality to the study', \"drug will be described as 'not related'.\", 'All AEs should be treated appropriately. The action(s) taken regarding the AE are classified as', 'follows:', 'Treatment for event:', 'None', 'Concomitant medication given or changed (to be specified on concomitant', 'medication form)', 'Others', 'Action taken with study medication:', 'Dose not changed', 'Dose reduced', 'Dose interrupted', 'Dose withdrawn', 'Page 48 of 75']\n\n###\n\n", "completion": "END"}